Silmitasertib sodium salt

TargetMol
Product Code: TAR-T15024
Supplier: TargetMol
CodeSizePrice
TAR-T15024-2mg2mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15024-5mg5mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15024-1mL1 mL * 10 mM (in DMSO)£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15024-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15024-25mg25mg£220.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T15024-50mg50mg£341.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Silmitasertib sodium salt is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α).
CAS:
1309357-15-0
Formula:
C19H11ClN3NaO2
Molecular Weight:
371.76
Pathway:
Metabolism; Autophagy; Stem Cells
Purity:
0.9949
SMILES:
[Na+].[O-]C(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21
Target:
Casein Kinase; Autophagy

References

1. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. 2. Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of ?-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203. 3. Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. Oncotarget. 2016 Jan 12;7(2):1323-40. 4. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.